Compare Dyne Therapeutics Inc. Common Stock (DYN) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs KraneShares CSI China Internet ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while KraneShares CSI China Internet ETF trades at $24.14 (market cap $4.51B). The key difference: KraneShares CSI China Internet ETF is the larger of the two by market cap, and KraneShares CSI China Internet ETF is more actively traded (12,272,723 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and KraneShares CSI China Internet ETF for 59 Days on average.
| DYN | KWEB | |
|---|---|---|
Market Cap | $2.86B | $4.51B |
Volume | 3,341,579 | 12,272,723 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $41.35 |
52-Week Low | $14.60 | $23.63 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KWEB trades at $24.72, down 0.12% with neutral technical signals. The ETF faces mixed institutional activity amid ongoing U.S.-China trade dynamics. Recent news highlights China's economic challenges including industrial overcapacity and trade rebalancing pressures, while corporate profits showed a 26% Q2 surge according to Zacks Investment Research on September 8, 2026.
The outlook remains cautious due to geopolitical tensions and China's economic headwinds. Investment opportunity exists if U.S.-China relations improve, but risks include trade protectionism and domestic consumption weakness. Technical indicators suggest limited near-term momentum with key support at $25.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
